$20.34
-0.34 (-1.64%)
Open$20.59
Previous Close$20.68
Day High$20.68
Day Low$19.90
52W High$22.88
52W Low$8.67
Volume—
Avg Volume65.8K
Market Cap277.30M
P/E Ratio—
EPS$-0.27
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+17.9% upside
Current
$20.34
$20.34
Target
$23.98
$23.98
$18.55
$23.98 avg
$27.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 105.35M | 117.42M | 23.45M |
| Net Income | -10,159,897 | -10,191,604 | 5.38M |
| Profit Margin | -9.6% | -9.2% | 22.9% |
| EBITDA | -5,303,552 | -5,615,664 | 8.65M |
| Free Cash Flow | — | — | 4.59M |
| Rev Growth | -10.3% | -10.3% | -4.1% |
| Debt/Equity | — | — | 0.39 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.35 | -1.10% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $419.87 | +0.42% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $150.65 | -1.02% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $525.69 | -0.38% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | +0.00% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $252.46 | -1.14% | 41.4 | 33.44B |